Lyell Immunopharma, Inc. (LYEL)
NASDAQ·Healthcare·Biotechnology
$21.49
-5.00%
Mkt Cap $522.79M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 12, 2026 | $15.25K | $6.00K | -60.66% | -$2.15 | -$7.68 | -257.21% | — | — |
| Q4 2025 Nov 12, 2025 | — | $15.00K | — | -$2.81 | -$2.13 | +24.20% | — | — |
| Q3 2025 Aug 12, 2025 | $4.00K | $8.00K | +100.00% | -$3.80 | -$2.89 | +23.95% | — | — |
| Q2 2025 May 13, 2025 | — | $7.00K | — | -$3.80 | -$3.60 | +5.26% | — | — |
| Q1 2025 Mar 11, 2025 | — | $11.00K | — | -$0.18 | -$0.72 | -300.00% | — | — |
| Q4 2024 Nov 7, 2024 | — | $34.00K | — | -$0.20 | -$0.17 | +15.00% | — | — |
| Q3 2024 Aug 7, 2024 | $3.25K | $13.00K | +300.00% | -$0.20 | -$0.18 | +10.00% | — | — |
| Q2 2024 May 6, 2024 | $1.00K | $3.00K | +200.00% | -$0.20 | -$0.24 | -20.00% | — | — |
| Q1 2024 Feb 28, 2024 | $3.25K | $13.00K | +300.00% | -$0.21 | -$0.20 | +4.76% | — | — |
| Q4 2023 Nov 7, 2023 | $6.25K | $25.00K | +300.00% | -$0.27 | -$0.20 | +25.93% | — | — |
| Q3 2023 Aug 8, 2023 | $18.00K | $27.00K | +50.00% | -$0.30 | -$0.26 | +13.33% | — | — |
| Q2 2023 May 4, 2023 | -$17.50K | $65.00K | +471.43% | -$0.28 | -$0.27 | +3.57% | — | — |
| Q1 2023 Feb 28, 2023 | $16.13M | $48.39K | -99.70% | -$0.31 | -$0.03 | +90.32% | — | — |
| Q4 2022 Nov 8, 2022 | $1.80M | $3.00K | -99.83% | -$0.34 | -$0.28 | +17.65% | — | — |
| Q3 2022 Aug 4, 2022 | $17.87M | $35.74M | +100.00% | -$0.31 | -$0.15 | +51.61% | — | — |
| Q2 2022 May 10, 2022 | $776.50K | $553.00K | -28.78% | -$0.29 | -$0.28 | +3.45% | — | — |
| Q1 2022 Mar 29, 2022 | $2.64M | $2.82M | +6.79% | -$0.28 | -$0.18 | +35.71% | — | — |
| Q4 2021 Nov 12, 2021 | $3.47M | $2.75M | -20.59% | -$0.27 | -$0.20 | +25.93% | — | — |
| Q3 2021 Aug 12, 2021 | $2.63M | $2.63M | +0.00% | -$0.36 | -$0.89 | -147.22% | — | — |
| Q2 2021 Jun 18, 2021 | — | $2.31M | — | — | -$0.18 | — | — | — |